[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550412":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":33,"locations":41,"responsibleParty":184,"collaborators":25,"id":186,"slug":187,"hasResults":188,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":188,"sex":194,"minAge":195,"maxAge":25,"enrollmentInfo":196,"targetDuration":25,"studyType":199,"phases":200,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},{"fullName":5,"class":6},"University of Alberta","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose-intensity","EXPERIMENTAL","The intervention arm will consist of low dose-intensity CRRT, defined as the hourly delivery of a total effluent of 10-15 mL\u002Fkg\u002Fhr while receiving CRRT. The intervention dose-intensity is based on the rationale that 10-15 mL\u002Fkg\u002Fhr is the lower threshold of dose-intensity currently provided in clinical practice and prior observational data showing this threshold is tolerated and safe.",[13],"Device: Continuous Renal Replacement Therapy (CRRT)",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard dose-intensity","ACTIVE_COMPARATOR","The control arm will receive a dose-intensity CRRT of 25-30 mL\u002Fkg\u002Fhr while receiving CRRT, aligned with local practice and information by international clinical practice guidelines. The control dose-intensity is based on the rationale that this is currently recommended in clinical practice guidelines and is commonly applied in routine practice.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Continuous Renal Replacement Therapy (CRRT)","Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration\u002Fdialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).",[9,15],null,[27,30],{"name":28,"affiliation":5,"role":29},"Sean M Bagshaw, MD","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":29},"Ron Wald","St. Michael's Hospital (Unity Health)",[34,38],{"name":28,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","780-248-1256","bagshaw@ualberta.ca",{"name":39,"role":35,"phone":25,"phoneExt":25,"email":40},"Ellen Morrison, PhD","ejmorris@ualberta.ca",[42,63,83,95,111,127,138,150,166],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Mayo Clinic","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-92.4699,44.02163,{"lat":54,"lon":53},[57,60],{"name":58,"role":35,"phone":25,"phoneExt":25,"email":59},"Kianoush Kashani, MD, MS","Kashani.Kianoush@mayo.edu",{"name":61,"role":35,"phone":25,"phoneExt":25,"email":62},"Mitchell Strand","Strand.Mitchell@mayo.edu",{"facility":64,"status":44,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University of Alberta Hospital","Edmonton","Alberta","T6G 2B7","Canada","CA",{"type":51,"coordinates":71},[72,73],-113.46871,53.55014,{"lat":73,"lon":72},[76,79],{"name":77,"role":35,"phone":78,"phoneExt":25,"email":37},"Sean Bagshaw, MD","587-984-4662",{"name":80,"role":35,"phone":81,"phoneExt":25,"email":82},"Caylin Chadwick","780-492-9951","Caylin.Chadwick@ahs.ca",{"facility":84,"status":44,"city":65,"state":66,"zip":25,"country":68,"countryCode":69,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"Grey Nuns Hospital",{"type":51,"coordinates":86},[72,73],{"lat":73,"lon":72},[89,92],{"name":90,"role":35,"phone":25,"phoneExt":25,"email":91},"Janek Senaratne, MD","janeks@ualberta.ca",{"name":93,"role":35,"phone":25,"phoneExt":25,"email":94},"Iqra Choudhry","Iqra.Choudhry@covenanthealth.ca",{"facility":96,"status":44,"city":97,"state":66,"zip":98,"country":68,"countryCode":69,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Sturgeon Community Hospital","St. Albert","T8N 6C4",{"type":51,"coordinates":100},[101,102],-113.63533,53.63344,{"lat":102,"lon":101},[105,108],{"name":106,"role":35,"phone":25,"phoneExt":25,"email":107},"Oleksa Rewa, MD","rewa@ualberta.ca",{"name":109,"role":35,"phone":25,"phoneExt":25,"email":110},"Bobby Guobadia","Bobby.Guobadia@albertahealthservices.ca",{"facility":112,"status":44,"city":113,"state":114,"zip":25,"country":68,"countryCode":69,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Hamilton General Hospital","Hamilton","Ontario",{"type":51,"coordinates":116},[117,118],-79.84963,43.25011,{"lat":118,"lon":117},[121,124],{"name":122,"role":35,"phone":25,"phoneExt":25,"email":123},"Maureen Meade, MD","meadema@mcmaster.ca",{"name":125,"role":35,"phone":25,"phoneExt":25,"email":126},"Lori Hand","handlori@hhsc.ca",{"facility":128,"status":44,"city":129,"state":114,"zip":130,"country":68,"countryCode":69,"cosmosGeoPoint":25,"geoPoint":25,"contacts":131},"Sunnybrook Health Sciences Centre","North York","M4N 3M5",[132,135],{"name":133,"role":35,"phone":25,"phoneExt":25,"email":134},"Neill Adhikari, MD","neill.adhikari@sunnybrook.ca",{"name":136,"role":35,"phone":25,"phoneExt":25,"email":137},"Valentin Smechuk","valentin.smechuk@sri.utoronto.ca",{"facility":139,"status":44,"city":140,"state":114,"zip":25,"country":68,"countryCode":69,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"St Michael's Hospital","Toronto",{"type":51,"coordinates":142},[143,144],-79.39864,43.70643,{"lat":144,"lon":143},[147],{"name":148,"role":35,"phone":25,"phoneExt":25,"email":149},"Ron Wald, MD","Ron.Wald@unityhealth.to",{"facility":151,"status":44,"city":152,"state":153,"zip":25,"country":68,"countryCode":69,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Regina General Hospital\u002FSaskatchewan Health Authority","Regina","Saskatchewan",{"type":51,"coordinates":155},[156,157],-104.6178,50.45008,{"lat":157,"lon":156},[160,163],{"name":161,"role":35,"phone":25,"phoneExt":25,"email":162},"Bhanu Prasad, MBBS MRCP (UK) CCST FRCPC","bprasad@sasktel.net",{"name":164,"role":35,"phone":25,"phoneExt":25,"email":165},"Aarti Garg","research1.drprasad@sasktel.net",{"facility":167,"status":44,"city":168,"state":25,"zip":169,"country":170,"countryCode":171,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Guy's & St Thomas' Hospitals","London","SE1 9RT","United Kingdom","UK",{"type":51,"coordinates":173},[174,175],-0.12574,51.50853,{"lat":175,"lon":174},[178,181],{"name":179,"role":35,"phone":25,"phoneExt":25,"email":180},"Marlies Ostermann, MD","m.ostermann@nhs.net",{"name":182,"role":35,"phone":25,"phoneExt":25,"email":183},"Karina Cheung","karina.cheung@nhs.net",{"type":185,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100550412","low-dose-intensity-vs-standard-dose-intensity-continuous-renal-replacement-therapy-in-critically-ill-patients-wisdom-100550412",false,"NCT06446739","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)","LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM): A Pilot Randomized Trial","WISDOM","Inclusion Criteria:\n\n* age ≥ 18 years\n* weight ≥ 55 kg\n* plan to initiate CRRT or within 24 hours of having started CRRT for AKI\n* expected to survive and receive CRRT for a duration of ≥ 48 hours\n* able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).\n\nExclusion Criteria:\n\n* indication for sustained higher dose-intensity CRRT as designated by the attending clinicians\n* end-stage kidney disease receiving maintenance dialysis\n* receipt of any RRT for AKI during the current hospitalization\n* inability to comply with the requirements of the study protocol.","ALL","18 Years",{"count":197,"type":198},100,"ESTIMATED","INTERVENTIONAL",[201],"NA","An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive a continuous form of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.",[204,205],"Acute Kidney Injury","Dialysis; Complications",[207,208,209,210,211],"acute kidney injury","continuous renal replacement therapy","dose-intensity","randomized trial","pilot feasibility","2026-04-24",{"date":214,"type":215},"2026-04-28","ACTUAL",{"date":217,"type":215},"2024-11-14",{"date":219,"type":198},"2027-06",{"name":5,"class":6},9]